What the FDA labels say about taking them together
Busulfan and ifosfamide
Ifosfamide's FDA label of December 2, 2024 names busulfan in its warnings and precautions section; the busulfan labels PlainMeds reads (2) do not name ifosfamide. The ifosfamide label: “Hemorrhagic cystitis is dose‑dependent and the risk is increased with past or concomitant radiation of the bladder or busulfan treatment.”
Check it at the source: the busulfan FDA label on DailyMed (effective June 27, 2024, Eugia US LLC); the ifosfamide FDA label on DailyMed (effective December 2, 2024).
What does the busulfan label say about ifosfamide?
Busulfan's label (effective June 27, 2024) and its 1 other brand-application label do not name ifosfamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Busulfan), Eugia US LLC, effective June 27, 2024 (SPL set 06883ac0-4b2a-4f26-89bf-512d37b9ba7f), via openFDA; the full label on DailyMed
What does the ifosfamide label say about busulfan?
Ifosfamide label, warnings and precautionsHemorrhagic cystitis is dose‑dependent and the risk is increased with past or concomitant radiation of the bladder or busulfan treatment.
Source: FDA drug label (IFEX), Baxter Healthcare Corporation, effective December 2, 2024 (SPL set b7241707-7538-4d1a-91e7-3a25a91e0b9a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Busulfan | Ifosfamide | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | A presentation being discontinued | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once